Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A multicenter phase III randomized trial comparing Taxotere administered either weekly or every three weeks in combination with prednisone versus Mitoxantrone in combination with prednisone for metastatic hormone-refractory prostate cancer
Docetaxel
RP56976-V-327
Not available
Prostatic Neoplasm, Prostate Cancer
Phase 3
 
Datasets and document are available as per Sanofi Policy and criteria
August 2017

Powered by ideaPoint, Inc.